0001214659-17-003555.txt : 20170522 0001214659-17-003555.hdr.sgml : 20170522 20170522204512 ACCESSION NUMBER: 0001214659-17-003555 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170520 FILED AS OF DATE: 20170522 DATE AS OF CHANGE: 20170522 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Anthera Pharmaceuticals Inc CENTRAL INDEX KEY: 0001316175 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201852016 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 25801 INDUSTRIAL BOULEVARD, SUITE B CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (510) 856-5600 MAIL ADDRESS: STREET 1: 25801 INDUSTRIAL BOULEVARD, SUITE B CITY: HAYWARD STATE: CA ZIP: 94545 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dickinson Klara CENTRAL INDEX KEY: 0001339895 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34637 FILM NUMBER: 17862491 MAIL ADDRESS: STREET 1: 5000 SHORELINE COURT, SUITE 101 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 marketforms-38869.xml PRIMARY DOCUMENT X0306 4 2017-05-20 0001316175 Anthera Pharmaceuticals Inc ANTH 0001339895 Dickinson Klara 25801 INDUSTRIAL BLVD., SUITE B HAYWARD CA 94545 false true false false Chief Regulatory Officer Stock option (right to buy) 1.63 2017-05-20 4 A false 43750 0 A 2027-05-20 Common Stock 43750 43750 D This stock option vests monthly in 36 equal installments. The vesting commencement date is May 20, 2019. Vesting of 25% if this option shall be accelerated on interim data of 75% patients enrolled in the Company's RESULT Phase 3 clinical trial, whichever is earlier. Following an acceleration of vesting of the options, the remaining unvested options shall vest in equal monthly installments through the remaining vesting period such that the entire award becomes fully vested 36 months from the vesting commencement date. This option will expire on May 20, 2027. /s/ Klara Dickinson 2017-05-22